Pricing Log in Create free account
Saturday 17 October 2026 Export NTRB’s income statement to Excel — free account

Nutriband Inc.

NTRB Healthcare Biotechnology

Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025. In the quarter to July 2026, revenue fell 29.7%, EPS grew 96.7%, free cash flow grew 55.5% and total debt fell 46.9%, each against the same quarter a year earlier.

6.22 0.05 −0.80%
Market cap
$76.2M
P/E
0.0×
Fwd P/E
4.6×
Dividend yield
—
F-score
3/9
Altman Z
27.17
Beneish M
−3.51
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 56.81%

Capital & Financial Ratios $m

Market Cap 76.21
Revenue 1.62
Net Income (6.96)
Free Cash Flow (3.63)
Net Debt (3.40)
Current Ratio 4.21 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 4.55
P/S ratio 46.74 (above 10: high)
P/B ratio 14.20 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth (526.26%) (below 0%: weak)
Next Y EPS Growth 125.32% (at or above 15%: strong)
Next Y revenue growth 34.04% (at or above 10%: strong)
Next 5Y EPS Growth 9.36%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 44.7×, against a ten-year median of 28.2×; over the ten years it ranged from 8.7× in 2023 to 417× in 2019.
P/S against its own 10 years 70.45%
10-year low 10-year high
P/B against its own 10 years 62.44%
10-year low 10-year high
EV/Sales against its own 10 years 69.63%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 0 4 5 3
Receivables 0 0 0 0
Inventory 0 0 0 0
Other — — — —
1 5 5 4
2024 2025 2026 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other — — — —
1 1 1 1

Compound Annual Growth %

10y 5y 3y
Sales — 16.63% (0.69%)
Cash Flow — 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (1.25%) (7.98%)

Revenue $m

Apr Jul Oct Jan Year
’26 0 0 — — —
’26 1 1 0 0 2
’25 0 0 1 1 2
’24 0 1 0 1 2
’23 0 0 1 1 2
’22 0 0 0 0 1
’21 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Apr Jul Oct Jan Year
’26 (1) (1) — — —
’26 (1) (1) (2) (1) (5)
’25 (1) (2) (1) (1) (5)
’24 (1) (1) (1) (1) (4)
’23 (1) (1) (1) (1) (3)
’22 0 0 (1) (1) (3)
’21 0 0 0 0 0
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Apr Jul Oct Jan Year
’26 (1) (1) — — —
’26 (1) (1) (2) (1) (5)
’25 (1) (2) (1) (1) (5)
’24 (1) (1) (1) (1) (4)
’23 (1) (1) (1) (1) (3)
’22 0 0 (1) (1) (3)
’21 0 0 0 0 0
Fiscal quarters ending in the months shown.

EPS $

Apr Jul Oct Jan Year
’26 (0.10) (0.07) — — —
’26 (0.12) (2.12) (0.32) (0.08) (2.58)
’25 (0.21) (0.15) (0.12) (0.51) (0.99)
’24 (0.13) (0.11) (0.22) (0.23) (0.69)
’23 (0.08) (0.12) (0.14) (0.21) (0.53)
’22 (0.04) (0.07) (0.23) (0.46) (0.81)
’21 (0.07) (0.03) (0.01) (0.33) (0.44)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to January

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 5.31 5.66 8.57 5.16 0.86 2.41 1.53 2.22 3.90 2.80

Analyst estimates 2027–2029

Powerpack
High 7.03 43.54 40.80 16.92 27.43 8.96 5.15 9.60 11.78 9.19
People
People Employees 2 10 7 3 5 13 3 3 3 3
Revenue/emp, $m 0.00 0.00 0.04 0.12 0.19 0.11 0.69 0.70 0.71 0.68
Income, $m
Income, $m Revenue — — 0 0 1 1 2 2 2 2
Gross margin, % — — (17.53) (48.17) 33.52 35.46 36.08 41.34 34.74 27.80
EBT 0 (3) (3) (3) (3) (6) (4) (5) (10) (8)
EBT margin, % 0.00 0.00 (1,358.01) (734.38) (310.78) (434.26) (215.59) (263.05) (489.96) (404.07)
Net income 0 (3) (3) (3) (3) (6) (4) (5) (10) (8)
Depreciation — 3 0 0 0 3 1 0 4 0
Per share, $
Per share, $ Revenue 0.00 0.00 0.04 0.06 0.14 0.18 0.25 0.26 0.20 0.18
Earnings (0.01) (0.12) (0.53) (0.43) (0.44) (0.81) (0.53) (0.69) (0.99) (2.58)
Cash flow (0.01) 0.00 (0.18) (0.14) (0.04) (0.35) (0.35) (0.44) (0.44) (0.44)
Capex 0.00 0.00 0.00 0.00 0.00 (0.01) (0.01) (0.01) (0.01) 0.00
Free cash flow (0.01) 0.00 (0.18) (0.14) (0.04) (0.36) (0.36) (0.45) (0.44) (0.44)
Book value 0.00 0.01 0.39 0.03 1.06 1.50 1.01 0.81 0.61 0.57
Shares, m 25 22 6 6 7 8 8 8 11 12
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — 0.00 201.26 110.08 20.92 14.85 9.96 41.10 26.81
P/B — — 64.12 425.36 14.61 2.51 3.60 3.22 13.68 8.18
EV/Sales — — 0.00 201.42 110.25 17.60 13.97 9.79 39.14 24.61
EV/FCF — — (138.53) (83.08) (345.35) (8.66) (9.48) (5.70) (17.75) (9.75)
Cash, $m
Cash, $m Operating cash flow 0 0 (1) (1) 0 (3) (3) (4) (5) (5)
Capex — — 0 — — 0 0 0 0 0
Free cash flow 0 0 (1) (1) 0 (3) (3) (4) (5) (5)
Balance, $m
Balance, $m Working capital 0 0 0 (2) (2) 5 2 0 4 4
Total debt 0 0 0 0 0 0 0 0 0 0
Net debt 0 0 0 0 0 (5) (2) 0 (4) (5)
Shareholders’ equity 0 0 2 0 7 12 9 6 6 7
Returns, %
Returns, % ROA (796.32) (2,637.61) (224.13) (108.75) (48.38) (56.23) (40.40) (64.63) (139.89) (400.11)
ROIC (1,454.81) (1,094.32) (105.69) (528.95) (22.51) (54.03) (41.82) (50.54) (295.49) (242.88)
ROE (2,608.62) (3,695.57) (263.74) (210.98) (80.49) (67.18) (43.89) (73.08) (162.94) (458.49)
Negative figures in brackets.

All 10 years →

Fiscal years to Jan 2026 · latest quarter Jul 2026

Charts ten years each

Nutriband Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CLLS Cellectis S.A. $79.9M — (loss-making) — −62.05% (below 0%: shrinking) n/m −36.95% (below 0%: shrinking) 100.00% (340.69%) Compare
PMN Promis Neurosciences $78.0M — (loss-making) — 0.00% n/m −169.46% (below 0%: shrinking) 0.00% 0.00% Compare
PTHS Pelthos Therapeutics Inc. $77.6M — (loss-making) — (loss-making) — n/m −1,614.99% (below 0%: shrinking) 76.86% (111.02%) Compare
TELO Telomir Pharmaceuticals, Inc. $77.3M — (loss-making) — — n/m −45.34% (below 0%: shrinking) — 0.00% Compare
NTRB Nutriband Inc. $76.2M — (loss-making) 4.6× −29.72% (below 0%: shrinking) n/m +55.46% (above 0%: growing) 41.58% (203.57%)
CRDF Cardiff Oncology, Inc. $75.5M — (loss-making) — (loss-making) −14.05% (below 0%: shrinking) n/m −41.36% (below 0%: shrinking) 100.00% (9,245.19%) Compare
ACRV Acrivon Therapeutics, Inc. $75.4M — (loss-making) — — n/m +12.59% (above 0%: growing) 0.00% 0.00% Compare
OKYO OKYO Pharma Limited Sponsored ADR $75.1M — (loss-making) — — n/m +37.39% (above 0%: growing) 0.00% — Compare
PDSB PDS Biotechnology Corporation $72.8M — (loss-making) — — n/m +69.32% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $76.4M — — −14.05% — −39.15% 0.00% 0.00%

All 614 Biotechnology stocks →

Nutriband Inc. (NTRB) key facts

  • Concern: Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025.
  • Nutriband Inc. (NTRB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, NTRB traded at $6.22, a market capitalization of $76.2 million.
  • Return on equity was −458.5% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 27.17 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Nutriband Inc. (NTRB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/NTRB · Data as of Jul 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com